Evaluation of the effects of pioglitazone on perivascular adipose tissue function, properties, and structure in a rat model of type-2 diabetes
Canadian Journal of Physiology and Pharmacology · 2025
DOI: 10.1139/cjpp-2024-0084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2025. Verfasst von Erkan Civelek und 5 weiteren Autor:innen. Beteiligte Einrichtung: Istanbul University, Faculty of Pharmacy, Department of Pharmacology, Istanbul, Turkey. Hauptthemen laut MEDLINE: Pioglitazone, Diabetes Mellitus, Type 2, Adipose Tissue. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 79 Literaturangaben. Gefördert von: The Scientific and Technological Research Council of Turkey.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Perivascular adipose tissue (PVAT) plays an important role in many physiological and pathological processes, such as regulation of vascular tone. The aim of this study is to evaluate the effects of pioglitazone on functional, structural, and biochemical properties of PVAT in an experimental model of type-2 diabetes (T2DM). T2DM was induced by high-fat-diet/low-dose-streptozotocin in rats, and pioglitazone (20 mg/kg/p.o.) was administered for 6 weeks. Changes in biochemical parameters, PVAT-mass, vascular-reactivity in thoracic-aorta, as well as PVAT adipocytokine and PPARG-expression levels, and histopathology were evaluated. Pioglitazone administration improved blood glucose and lipid profiles in T2DM. Pioglitazone did not change the anticontractile effect of PVAT on aortic contractile reactivity and besides, had no influence on endothelium-dependent and -independent relaxation responses. Pioglitazone administration increased PVAT-mass and tumor necrotizing factor-α levels, while adiponectin, leptin, and interleukin-6 levels were unchanged. Also, a prominent increase was observed in PPARG-expression in T2DM-Pio group. Moreover, pioglitazone decreased liver steatosis, aortic wall thickening, and myocardial damage, whereas increased adipocyte size and adiposity in PVAT. Overall, pioglitazone treatment changed the mass and in part the inflammatory profile of PVAT but did not modify vasoreactivity in T2DM. This study provides novel findings in relationship with the adipogenic effect of pioglitazone and PVAT function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Istanbul University, Faculty of Pharmacy, Department of Pharmacology, Istanbul, Turkey.
- Istanbul University, Graduate School of Health Sciences, Istanbul, Turkey.
- Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Istanbul, Turkey.
- Biruni University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Istanbul, Turkey.
- Bezmialem Vakif University, Faculty of Medicine, Department of Medical Pathology, Istanbul, Turkey.
ORCID-Profile: Deniz Kaleli Durman
Förderung
- The Scientific and Technological Research Council of Turkey
Zitieren
APA
Civelek, E., Karaman, E. F., Özden, S., Büyükpınarbaşılı, N., Uydeş Doğan, B., & Kaleli Durman, D. (2025). Evaluation of the effects of pioglitazone on perivascular adipose tissue function, properties, and structure in a rat model of type-2 diabetes. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2024-0084
Vancouver
Civelek E, Karaman EF, Özden S, Büyükpınarbaşılı N, Uydeş Doğan B, Kaleli Durman D. Evaluation of the effects of pioglitazone on perivascular adipose tissue function, properties, and structure in a rat model of type-2 diabetes. Canadian Journal of Physiology and Pharmacology. 2025. doi:10.1139/cjpp-2024-0084
BibTeX
@article{Civelek2025,
author = {Civelek, Erkan and Karaman, Ecem Fatma and Özden, Sibel and Büyükpınarbaşılı, Nur and Uydeş Doğan, B Sönmez and Kaleli Durman, Deniz},
title = {Evaluation of the effects of pioglitazone on perivascular adipose tissue function, properties, and structure in a rat model of type-2 diabetes},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2025},
doi = {10.1139/cjpp-2024-0084}
}
EUVIMED